Redeye leaves a comment following Alzinova’s announcement of a completed primary analysis of the pha...
Stark Q4 cementerar återgång till pre-pandeminivåer Inför Q4 hade vi förväntningar på starkt momentu...
SRV will release its Q4 results on Feb 1; we expect revenue to turn to growth with ongoing business ...
Redeye updates on EG7 ahead of its Q4-results (due 13 February) where we expect a stable year-end pe...
Ahead of NoHo's Q4 report, due on 15 February, we adjust our estimates to reflect the guidance updat...
Redeye has a positive take on today’s news that Alzecure has advanced ACD137 as a drug candidate as ...
We cut '23e-'25e adj. EBITA by 13-10% Inflation data for Q4 suggest negative-to-neutral volume/mix T...
Our estimates for net sales and EBIT are slightly above consensus for Q4.
Q4e: Tuesday, 30 January at 8:00 CET Healthy 2024 with 6% organic growth and solid margin expansion ...
Redeye updates its estimates after Ependion’s Q4 2023 report, which was slightly weaker than our est...
DT reports Q4 on Feb 1. MBU may not grow much this year, yet organic SBU-driven recovery and recent ...
Consti reports its Q4 figures on 2nd of February. We expect a solid finish to the year despite conti...
Rapportkommentar Diamyds rapport för det första kvartalet 2023/2024 var i linje med våra förväntning...
Neutralt resultat givet förutsättningarna BE Group rapporterade ett i våra ögon neutralt resultat gi...
Redeye updates our outlook after Q4 2023. XVIVO delivers improved gross margins with a softer organi...
Vera has a BAFF/APRIL B-Cell modulator based IgAN candidate called Atacicept, which has delivered 2b...
EcoRub har idag publicerat bolagets Q4-rapport och visar på fortsatta framsteg.
Acconeer yesterday announced a design win of over SEK 50m for access control related to a major Japa...
Redeye comments on Mestro’s launch of its Data-as-a-Service (DaaS) solution.
XVIVO delivers a soft 12% organic growth in the last quarter of 2023 (based on CER excluding acquisi...
